Micrornas Expression Profile in Solid and Unicystic Ameloblastomas by Setién Olarra, Amaia et al.
RESEARCH ARTICLE
MicroRNAs expression profile in solid and
unicystic ameloblastomas
A. Setie´n-Olarra1, X. Marichalar-Mendia1*, N. G. Bediaga2, P. Aguirre-Echebarria3, J.
M. Aguirre-Urizar1, A. Mosqueda-Taylor4
1 Oral Medicine and Pathology, Department of Stomatology II, University of the Basque Country (UPV/EHU),
Leioa, Spain, 2 BIOMICs Research Group, Lascaray Research Center, University of the Basque Country
(UPV/EHU), Miguel de Unamuno, Vitoria-Gazteiz, Spain, 3 Head and Neck Section. Service of Pathology.
University Hospital of Donostia. University of the Basque Country/EHU. San Sebastian, 4 Health Care




Odontogenic tumors (OT) represent a specific pathological category that includes some
lesions with unpredictable biological behavior. Although most of these lesions are benign,
some, such as the ameloblastoma, exhibit local aggressiveness and high recurrence rates.
The most common types of ameloblastoma are the solid/multicystic (SA) and the unicystic
ameloblastoma (UA); the latter considered a much less aggressive entity as compared to
the SA. The microRNA system regulates the expression of many human genes while its
deregulation has been associated with neoplastic development. The aim of the current
study was to determine the expression profiles of microRNAs present in the two most com-
mon types of ameloblastomas.
Material & methods
MicroRNA expression profiles were assessed using TaqMan® Low Density Arrays (TLDAs)
in 24 samples (8 SA, 8 UA and 8 control samples). The findings were validated using quanti-
tative RTqPCR in an independent cohort of 19 SA, 8 UA and 19 dentigerous cysts as
controls.
Results
We identified 40 microRNAs differentially regulated in ameloblastomas, which are related to
neoplastic development and differentiation, and with the osteogenic process. Further valida-
tion of the top ranked microRNAs revealed significant differences in the expression of 6 of
them in relation to UA, 7 in relation to SA and 1 (miR-489) that was related to both types.
Conclusion
We identified a new microRNA signature for the ameloblastoma and for its main types,
which may be useful to better understand the etiopathogenesis of this neoplasm. In addition,
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we identified a microRNA (miR-489) that is suggestive of differentiating among solid from
unicystic ameloblastoma.
Introduction
Odontogenic tumors (OT) represent a specific pathological category that is particularly inter-
esting due to its unique and complex etiopathogenesis that causes lesions with variable, some-
times unpredictable biological behavior. Although most OT are benign, some may exhibit
local aggressiveness and high recurrence rates [1,2]. One of such tumors is the ameloblastoma,
a neoplasm composed by proliferating odontogenic epithelium that resembles the enamel
organ, which may produce diverse clinical and histomorphological variants [2]. The most
common type of amelobastomas is the solid/multicystic (SA), but there is also an enterely cys-
tic variant, the unicystic ameloblastoma (UA), which is considered a much less aggressive
entity as compared to SA [1,2] and should therefore be identified and treated in a less aggres-
sive way.
To date, most molecular studies on ameloblastomas have focused largely on the search for
markers [3,4], as well as on the presence of genetic alterations [5–7], and, to a lesser extent, on
the epigenetic alterations present in these neoplasms [8,9] that helps to ensure diagnosis and
better define its prognosis. Recently, it has been shown that a hyperactive RAS–RAF–MAPK
pathway is closely associated with the pathogenesis of the ameloblastoma, either through
EGFR-mediated signalling or through frequent activating mutations in the BRAF gene [10].
MicroRNAs are small non-coding RNA molecules (21 to 25 base pairs in length) that regu-
late post-transcriptional gene expression. The microRNAs bind partially to the 3’ region of the
messenger RNA (mRNA) causing transcriptional repression or direct degradation of the
mRNA [11]. MicroRNAs are known to regulate some basic cellular biological processes, such
as growth, differentiation and cell death [12]; therefore, they may play an important role in
neoplastic development, acting as both oncogenes and suppressor genes [13].
Different studies in oral cancer [14,15] report differences between tumoral and normal tis-
sues when analyzing the expression profiles of microRNAs. In addition, changes in the expres-
sion profiles of microRNAs during malignant transformation of oral precancerous lesions
have also been described [16,17]. However, studies that analyze the role of alterations of micro-
RNAs in the development and progression of ameloblastomas are scarce [18].
The purposes of this study were to determine the expression profile of microRNAs present
in the two main types of ameloblastoma, the solid and the unicystic types, and to validate the
results in a set of independent samples.
Material and methods
We studied oral samples of formalin-fixed and paraffin-embedded biopsies (FFPE) of 70
patients diagnosed with SA (27 cases), UA (16 cases), and 27 cases of dentigerous cyst (DC).
These samples were obtained from the Oral Pathology Laboratory of the Metropolitan Auton-
omous University (Mexico) and the Oral and Maxillofacial Pathology Laboratory of the Uni-
versity of the Basque Country (EHU). In the screening phase of the SA group, a total of 8
patients (mean age, 30 years; SD, 12.2; female to male ratio, 1: 1) were included, whereas in the
validation phase 19 patients (mean age, 31.9 years; SD, 15.2; female to male ratio, 0.9: 1) were
included. Eight patients with UA were included in the screening phase (mean age, 18.9 years,
SD, 8.7, female-to-male ratio, 1: 1), and the other eight cases were studied in the validation
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phase (mean age, 19.9 years; SD, 6.7, female-to-male ratio, 1: 1). Finally, 27 patients diagnosed
with DC were included as a control group. In the screening phase, there were 8 cases (mean
age, 36 years; SD, 17.9; female-to-male ratio, 1: 1), while 19 were included in the validation
phase (mean age, 46.7 years; SD, 14.5; female -to-male ratio, 0.46: 1). The dentigerous cyst was
chosen as a control because it is a non-neoplastic odontogenic cystic lesion that presents an
epithelial component derived from the reduced epithelium of the enamel organ which is
included in the differential diagnosis of UA both clinically and at a microscopic level in spite
of its different biological behavior [19].
Table 1 shows the salient demographic characteristics of the three groups of lesions. In all
cases, the most representative areas of each lesion were chosen for study.
This study was carried out following the principles of the Declaration of Helsinki on Ethical
Principles for Medical Research Involving Human Subjects and was approved by the Ethics
Committee for Research of the University of the Basque Country / EHU (CEIAB / 204/2015).
The study followed a similar methodology to that described by Setie´n-Olarra et al. [17].
RNA isolation
The total RNA, in which the microRNA was included, was extracted from sections of the par-
affin blocks, which were previously dewaxed with xylol using the miRNeasy FFPE kit (Qiagen,
UK). The purity and concentration of the RNA were determined by the OD260 / 280/230 read-
ings using a NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific, Eugene, OR,
USA). The integrity of the RNA was determined by fluorometric quantification using the
Qubit 3 Fluorometer (Life Technologies, Foster City, CA, USA).
MicroRNA profiling
Expression profile analysis of microRNAs was performed in 24 samples (8 AS samples, 8 AU
samples, and 8 control samples) using TaqMan1 Low-Density Arrays (TLDAs) (Applied Bio-
systems, USA). In summary, the total RNA (150 ng) was converted to specific cDNA derived
from mature microRNAs using Megaplex ™ Primer Pools A and B (Applied Biosystems), fol-
lowed by a pre-amplification step using Megaplex Pre-amp Primers Pools A and B. Finally, a
total of 9 μl of the preamplifier product was loaded onto TaqMan1 Array Human MicroRNA
Cards. A 7900 real-time RT-PCR System (Applied Biosystems) was used to run the assay.
MicroRNA quantitative RT-PCR
Subsequently, we validated the microRNAs identified in an independent set of 91 oral samples
(FFPE) (27 SA, 16 UA and 27 DC) by RT-qPCR using TaqMan1 microRNA assays (Applied
Biosystems).
Each microRNA was analyzed in triplicate and furthermore non-template RT controls were
carried out for each experiment. The Ct values of the target microRNAs were normalized with
the three normalizing microRNAs (miR-222, miR-17 and miR-106a), and the expression levels
Table 1. Demographic characteristics of the patients included in this study.
Screening (n = 24) Validation (n = 46)
Control (n = 8) UA (n = 8) SA (n = 8) Control (n = 19) UA (n = 8) SA (n = 19)
Gender n (%) Male 4 (50) 4 (50) 4 (50) 13 (68.4) 4 (50) 10 (52.6)
Female 4 (50) 4 (50) 4 (50) 6 (31.6) 4 (50) 9 (47.4)
Age(years) Mean (SD) 36 (17.9) 18.9 (8.7) 30 (12.2) 46.7 (14.5) 19.9 (6.7) 31.9 (15.2)
https://doi.org/10.1371/journal.pone.0186841.t001
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of each microRNA [relative amount (RQ)] were calculated using the method Comparison of
Ct: CtSAMPLE-CtMEANNORMALIZERS.
Data analysis
The data were analyzed using the software packages Sequence Detection System (SDS) and
Expression Suit (Life Technologies) as previously described by Bediaga et al. [20]. The Ct val-
ues were determined using an automatic baseline and a threshold of 0.1. Valid data were
imported into the HTqPCR package [21] for quality assessment, normalization, and statistical
significance tests of Ct values between different groups. The data were normalized using the
geometric mean of the entire expression of the set of microRNAs.
The microRNAs that showed a normalized performance similar to the expression value of
the geometric mean were proposed as normalizer candidates for the subsequent validation
phase, as previously described by Marabita et al. [22]. The miR-222, miR-17, and miR-106a
microRNAs proved to be the best set of normalizers, confirming their suitability as endoge-
nous normalizers with the algorithm software [23]. The difference in expression of the micro-
RNAs found between the different groups was further evaluated by empirical Bayes moderated
t-tests. All p-values obtained were adjusted by the Benjamini-Hochberg procedure. We
selected the microRNAs that showed a two-fold difference in the Fold Change value [Fold
Change (FC)> 2] and an adjusted p-value<0.05 between SA vs normal and UA vs normal “S1
Table”. For the identification of the different subgroups defined by expression profiles of
microRNAs, unsupervised cluster analyses were performed using the Euclidean distance
between the Ct values. On the other hand, the paired comparisons of the quantitative data
obtained in the RT-qPCR experiments were performed using the Mann-Whitney test. All tests
were two-tailed, and p-values <0.05 were considered statistically significant. Statistical ana-
lyzes carried out in the validation phase were performed using SPSS v18.
Results
Identification of aberrant expression profiles of microRNAs in SA and UA
The expression profile of 768 mature miRNAs was analyzed in a total of 24 samples. Of these,
56 were present in SA and 20 in UA. Visual approximation analyses based on unsupervised
clusters of these microRNAs resulted in a differentiated expression profile among the 3 groups
of lesions (Fig 1).
Next, we proceeded to analyze which miRNAs were differentially expressed in each group
(SA and UA) compared to the control. Using a significance level of p <0.05 (adjusted for mul-
tiple tests) and a FC 0.5 or 2 cutoff, 40 microRNAs were classified as dysregulated in the
ameloblastoma samples. Specifically, 38 microRNAs were classified as dysregulated in the SA
group (23 overexpressed and 15 underexpressed) and 6 in the UA group (5 overexpressed and
1 underexpressed). In turn, both groups shared 4 unregulated miRNAs versus the control
group (Fig 2).
The 13 microRNAs mostly deregulated among the SA and the control group and among
the UA and the control group were selected for a posterior validation in an independent set of
samples.
Validation of microRNAs expression profiles between UA and SA groups
After applying the inclusion criteria (|FC|<0.2 or> 5 and p adjusted <0.05), as previously
mentioned, biological validation was performed by RT-qPCR of the 13 differently regulated
miRNAs (hsa-miR-9, hsa-miR-135b, hsa-miR-194, hsa-miR-489, hsa-miR-592, hsa-miR-
MicroRNA profile in ameloblastoma
PLOS ONE | https://doi.org/10.1371/journal.pone.0186841 October 20, 2017 4 / 12
369-5p, hsa-miR-876-5p, hsa-miR-31, hsa-miR-135b, hsa-miR-211, hsa-miR-944, hsa-miR-
142-5p, hsa-miR-455-3p), in an independent set of 46 samples corresponding to 19 SA, 8 UA
and 19 controls.
When analyzing the expression of each miRNA, we observed statistically significant differ-
ences in 6 microRNAs among the UAs and the control group, (p<0.05) (hsa-miR-135b , hsa-
miR-592, hsa-miR-31, hsa-mir-135b, hsa-miR-944, hsa-miR-142-5p)). On the SA group, we
observed differences in the expression between SAs and the control group in seven out of the
13 microRNAs selected for biological validation (p<0.05), (hsa-miR-135b , hsa-miR- 489,
hsa-miR-592, hsa-miR-369-5p, hsa-miR-31, hsa-mir-135b, hsa-miR-944). When comparing
the SA group with the UA group, we only found statistically significant differences for micro-
RNA-489 (p = 0.016) (Table 2).
When analyzing the expression levels of the microRNAs selected for validation (Table 2),
we observed that 5 of them (hsa-miR-135b , hsa-miR-592, hsa-miR-31, hsa-mir-135b, hsa-
miR-944) have similar patterns of expression, i.e., there are statistically significant differences
between the UAs and the control group. There are also statistically significant differences
between the SAs and control group; however, when comparing the levels of expression of
these microRNAs between the UA and the SA groups, we did not find statistically significant
differences.
Fig 1. Unsupervised hierarchical clustering analysis using the differentially expressed microRNAs
separates SA, UA, and control tissues. The heatmap (Euclidean distance) represents the delta-Ct values.
Color heatmap correspond to microRNA expression as indicated in the color key: red (underexpressed) and
green (overregulated).
https://doi.org/10.1371/journal.pone.0186841.g001
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Discussion
Ameloblastoma is a benign odontogenic tumor that can exhibit a variably aggressive biological
behavior as evidenced by its infiltrative growth and marked tendency for recurrence [1,2].
Interestingly, the main variants of this neoplasm (SA and UA) show clear differences on its
prognosis, urging for a different surgical approach for each type, with less invasive procedures
being adequate to control most UA. However, sometimes it can be difficult to make a precise
pre-therapeutic diagnosis, so it may be important to elucidate if there are differences in the
molecular pathways that are involved in their development that could be of assistance in
Fig 2. A Venn diagram showing microRNA signatures in ameloblastoma types. Significantly
deregulated microRNAs (adjusted p-value <0.05 and FC0.5 or2) within the two groups compared with
control group. Upregulated in black and downregulated in red color.
https://doi.org/10.1371/journal.pone.0186841.g002
Table 2. Biological validation of the 13 microRNAs selected.
microRNA Chromosome Unicystic Ameloblastoma vs
Control
Solid Ameloblastoma vs Control Solid Ameloblastoma vs
Unicystic
FC p value FC p value FC p value
hsa-miR-135b* 1 8.52 <0.001 15.87 <0.001 1.86 0.283
hsa-miR-944 3 5.72 <0.001 8.91 <0.001 1.56 0.333
hsa-mir-135b 1 4.58 <0.001 5.67 <0.001 1.24 0.585
hsa-miR-31 9 3.59 <0.001 6.65 <0.001 1.85 0.051
hsa-miR-592 7 2.99 0.001 4.11 <0.001 1.20 0.515
hsa-miR-142-5p 17 1.55 0.006 1.11 0.133 0.72 0.26
hsa-miR-369-5p 14 0.79 0.333 0.66 0.015 0.84 0.856
hsa-miR-489 7 0.85 0.449 0.43 <0.001 0.50 0.016
hsa-miR-876-5p 9 24.31 0.055 1.53 0.163 0.55 0.836
hsa-miR-194* 1 1.58 0.669 1.30 0.503 0.83 0.644
hsa-miR-211 15 1.27 > 0.05 1.01 0.825 0.79 0.881
hsa-miR-9 1 0.99 0.929 0.73 0.307 0.74 0.407
hsa-miR-455-3p 9 0.98 0.735 0.83 0.402 0.85 0.821
FC: Fold Change; Statistically significant values are represented in bold.
https://doi.org/10.1371/journal.pone.0186841.t002
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differentiating among them [3]. Therefore, the search for new diagnostic and prognostic tools
that help improve the characterization of ameloblastomas and provide us with new therapeutic
strategies is a very important issue.
This study analyzes the expression profiles of micro-RNAs in ameloblastoma, and shows
that this neoplasm has aberrant expression profiles of microRNAs that may pose diagnostic
value.
In the screening phase we identified 40 microRNAs differently expressed in ameloblastoma.
In addition, we have observed a clear progression of alterations in the expression of micro-
RNAs from UA (6 altered microRNAs) to SA (38 altered microRNAs), 4 of which are shared
by both types of ameloblastoma. After validation, we recognized significant differences in 6
microRNAs in relation to UA, 7 to SA and in 1 (miR-489) in relation to both tumor types. We
consider that these results demonstrate a specific profile of altered microRNAs for these neo-
plasms, and the existence of a microRNA (miR-489) that is suggestive of differentiating
between the two major types of ameloblastoma.
MicroRNAs with a differential expression in both SA and UA when compared to the con-
trol group are the microRNA miR-135b, miR-135b , miR-31, miR-592 and miR-944.
It has been previously described [24] that miR-135b is a regulator of mineralization in the
process of osteoblastic stem cell differentiation. In addition, a serum increase of miR-135b was
recognized in patients with multiple myeloma who present bone lesions, a finding that could
help to identify these patients [25]. There are also several studies [26,27] that linked deregula-
tion of miR-135b with the progression of some malignant neoplasms, such as squamous cell
carcinoma of the head and neck. Its overexpression would lead to an increase in cell prolifera-
tion, migration and the formation of cell colonies [26]. Recently, Nezu et al. [27] identified
miR-135b as a key regulator in myxoid liposarcoma, the overexpression of which would favor
neoplastic invasion and metastasis through the direct suppression of thrombospondin 2
(THBS2), a protein that mediates cell-extracellular matrix interactions. Furthermore, Jin et al.
[28] linked miR-135b with the stimulation of osteosarcoma recurrence and lung metastasis via
Notch and Wnt/β-Catenin signaling. Based on this information, we consider that overexpres-
sion of miR-135b observed in ameloblastoma could be related to tumor growth and regulation
of osteogenesis.
In relation to miR-31, studies indicate that it would play an important role in the regulation
of osteogenesis [29,30]. Recently, Weilner et al. [29] identified it as a crucial component during
the inhibition of the osteogenic process, recognizing elevated plasma levels of this microRNA
in patients with osteoporosis [29]. Furthermore, this microRNA could regulate osteogenic dif-
ferentiation by its direct binding to the STAB2 gene, which codes for a transmembrane recep-
tor that, in turn, regulates important processes such as angiogenesis and cell adhesion [30]. In
addition, miR-31 would also participate in different neoplastic processes, including oral squa-
mous cell carcinoma [31,32]. Siow et al. [31] indicated that its overexpression would be related
to the tumor stage, with a special relevance in the early stages, while others described [32] that
the activation of the EGFR-AKT-CEBPb pathway would promote overexpression of miR-31 in
oral cancer. Finally, it is important to mention that different authors [33–35] described a direct
association between the altered expression of miR-31 and the RAS-RAF-MAPK pathway,
resulting in cell growth and cell survival, and which is closely associated with ameloblastoma
pathogenesis, lung cancer [34] and colorectal cancer [33,35]. Edmonds et al. (2016) deter-
mined that miR-31 was not only highly overexpressed in lung adenocarcinoma but also signifi-
cantly correlated with patient survival. This microRNA is capable of promoting lung cancer by
subexpressing several regulators (SPRED1, SPRED2, SPRY1, RASA1, SPRY3 and SPRY4) in
RAS / MAPK signaling, which leads to an increase in the signaling of this pathway.
MicroRNA profile in ameloblastoma
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On the other hand, Sun et al. (2013) detected a significant overexpression of miR-31 in
colorectal cancer. In addition, these authors made an in silico identification and an in vitro vali-
dation of one of the targets of this microRNA, RASA1, which is a regulatory molecule of the
RAS-RAF-MAPK pathway. Moreover, Sun et al. (2013) demonstrated that miR-31 can activate
the RAS signaling pathway by inhibiting the RASA1 molecule, which would lead to increase
cell growth and would facilitate tumorogenesis.
In view of these results, we believe that miR-31 could be linked with the tumoral growth of
the ameloblastoma and with the regulation of osteogenesis.
Different studies [36,37] linked the alterations of miR-592 to neoplastic development in
humans. Furthermore, its overexpression in colorectal cancer, in which it would promote
tumor progression and metastasis, through the FoxO3A target, a transcription factor regulat-
ing apoptosis [38]. Liu et al. [39] described this overexpression of miR-592 in colorectal cancer
associating it to the size of the tumor, the distance of the metastases and the patient survival.
With these data, we consider that alterations in miR-592 expression in ameloblastomas would
be mainly linked with tumor growth and progression.
MicroRNA-944 has been associated with the P63 gene, which participates in the process of
proliferation and differentiation of keratinocytes [40]. It has been related to the induction of
keratins 1 and 10 by inhibiting the expression of ERK signaling and the upregulation of p53
expression [40]. Overexpression of miR-944 is also described in uterine cervix cancer [41], in
which it would promote proliferation, migration and cell invasion [41]. Recently, He et al. [42]
described its overexpression in breast cancer, suggesting a link with cell proliferation and
metastasis. Based on these studies, we believe that the overexpression of miR-944 in ameloblas-
toma may be related to the processes of epithelial tumor differentiation and neoplastic
proliferation.
In our study, we were able to recognize significant differences in miR-489 expression
between SA and UA. Although the information on the functions of miR-489 so far is scarce,
Schoolmeesters et al. [43] pointed out that this microRNA could regulate the early osteogenic
differentiation in human mesenchymal stem cells, and play a critical role in the osteogenic pro-
cess. In addition, this microRNA has also been identified as a tumor suppressor in hypophar-
yngeal squamous cell carcinoma [44], lung cancer (NSCLC) [45], and breast cancer [46, 47].
In particular, Patel et al. [47] analyzed the expression profile of deregulated microRNAs in
HER2-positive breast cancer cells. Her2 is a receptor tyrosine kinase usually overexpressed in
20–30% of breast cancers and associated with poor prognosis and outcome. These authors
observed that miR-489 was underexpressed in this type of cancer, especially through the MAPK
pathway, In a later in vitro experiment in xenograft mice, they determined that overexpression
of this microRNA in HER2-positive breast cancer cells significantly inhibited cell growth and
decreased tumorigenicity and tumor growth. In summary, these authors suggest that these
results define a double-negative feedback loop involving miR-489 and the HER2-SHP2-MAPK
signaling axis that can regulate breast cancer cell proliferation and tumor progression and
might have therapeutic relevance for HER2-positive breast cancer [47].
Based on these facts, it could be suggested that the differences found in miR-489 expression
between the two types of ameloblastoma could play an important role to explain the different
aggressiveness observed in these entities.
The differences in miR-489 expression could be an important element in the differential
diagnosis between the two types of ameloblastomas, and therefore, it is essential to confirm
these results in a larger set of samples. Although a robust statistical approach was used, there
are also some limitations, such as the small number of UA included in the validation phase, or
the fact that total RNA was obtained from FFPE samples.
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In conclusion, our study identified an apparently specific profile of aberrant expression of
microRNAs for the main types of ameloblastoma. These results were validated in an indepen-
dent set of samples. MicroRNAs differentially expressed in ameloblastomas are related to neo-
plastic development, osteogenic process and neoplastic differentiation. In addition, we
identified a microRNA (miR-489) suggestive of differentiating between solid and unicystic
ameloblastomas. Our findings may be useful to open new avenues of study that will allow us to
better understand the etiopathogenesis of these neoplasms, as well as to improve their diagno-
sis and to define more effective treatments.
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